4D Molecular Therapeutics Inc (NAS:FDMT)
$ 8.39 0.215 (2.63%) Market Cap: 436.02 Mil Enterprise Value: -103.44 Mil PE Ratio: 0 PB Ratio: 0.74 GF Score: 63/100

4D Molecular Therapeutics Inc at Bank of America Global Healthcare Conference Transcript

May 09, 2023 / 11:20PM GMT
Release Date Price: $17.33 (+4.90%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

I'm Tazeen Ahmad. I'm one of the Senior SMID biotech analysts here at Bank of America. It's my pleasure to have our next presenting company management with us, specifically 4D Molecular Therapeutics.

With me for the next 30 minutes are a couple of members from the management team, Fred Kamal as well as CEO, David Kirn.

So David, I think while we're getting the slides situated, I think it's probably good for us to get an intro with the company, if you could for a couple of minutes, and then we can go into more details either on the slides or on Q&A.

David H. Kirn
4D Molecular Therapeutics, Inc. - Co-Founder, CEO & Director

Absolutely. Well, thanks for having us today, and good to see you all. At 4D Molecular Therapeutics, we're harnessing the power of directed evolution, which is a Nobel Prize-winning technology to invent customized AAV vectors for any tissue in the body, and we think this translates into best-in-class products across

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot